| 000 | 00933 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250516070607.0 | ||
| 264 | 0 | _c20120117 | |
| 008 | 201201s 0 0 cze d | ||
| 022 | _a0042-773X | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHaluzík, M | |
| 245 | 0 | 0 |
_a[Pathophysiological background for incretin therapy: is it capable of more than we think?]. _h[electronic resource] |
| 260 |
_bVnitrni lekarstvi _cNov 2011 |
||
| 300 |
_a897-902 p. _bdigital |
||
| 500 | _aPublication Type: English Abstract; Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 |
_aGlucagon-Like Peptide 1 _xagonists |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xpharmacology |
| 650 | 0 | 4 |
_aIncretins _xpharmacology |
| 700 | 1 | _aUrbanová, M | |
| 700 | 1 | _aHaluzíková, D | |
| 700 | 1 | _aTrachta, P | |
| 773 | 0 |
_tVnitrni lekarstvi _gvol. 57 _gno. 11 _gp. 897-902 |
|
| 999 |
_c21388141 _d21388141 |
||